Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bradley Callas

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cureus|March 3, 2026
Stereotactic Body Radiation Therapy in the Management of Recurrent Unresectable Retroperitoneal GanglioneuromaBradley Callas, Shyam Jani, Isheeta S Govardhan, et al.
Cancers|May 27, 2026
Precision-Oriented Reconstruction After Spinal Sarcoma Resection: Integrating Surgical Strategy, Biologic Risk, and Emerging TechnologiesTanner Carcione, Bradley Callas, Jack Thiara, et al.
Cancers|June 26, 2026
Evaluation Frameworks for Predictive and Generative Oncology AI: Current Standards, Cancer-Specific Gaps, and a Path Toward Clinical UseConnor D Yost, Bradley Callas, Peter Halligan, et al.
Leukemia & Lymphoma|December 17, 2024
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trialCaspian Oliai, Sunmin Park, Lloyd E Damon, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cureus|March 3, 2026
Stereotactic Body Radiation Therapy in the Management of Recurrent Unresectable Retroperitoneal GanglioneuromaBradley Callas, Shyam Jani, Isheeta S Govardhan, et al.
Cancers|May 27, 2026
Precision-Oriented Reconstruction After Spinal Sarcoma Resection: Integrating Surgical Strategy, Biologic Risk, and Emerging TechnologiesTanner Carcione, Bradley Callas, Jack Thiara, et al.
Cancers|June 26, 2026
Evaluation Frameworks for Predictive and Generative Oncology AI: Current Standards, Cancer-Specific Gaps, and a Path Toward Clinical UseConnor D Yost, Bradley Callas, Peter Halligan, et al.
Leukemia & Lymphoma|December 17, 2024
CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trialCaspian Oliai, Sunmin Park, Lloyd E Damon, et al.
Pageof 1